In Memoriam
16
19
1
49
2
8
1b
1d
18
3a
2b
7
60
1d
2 29
1d
25
Murray Grossman, M.D., Ed.D.
78
2b
7
60
Department: Neurology
4
1
23
1f
Graduate Group Affiliations
8
b
-
41
- Bioengineering 64
- Neuroscience e
1d
46
Contact information
30
4
3
3
3
2
4
b
1f
30
HUP
16 3400 SPRUCE ST.
27 4283
Philadelphia, PA 19104
26
16 3400 SPRUCE ST.
27 4283
Philadelphia, PA 19104
2c
Office: 2156623361
30
f
30
13
Education:
21 9 B.A. 1b (Psych/Soc/Engl) c
26 Union College, 1972.
21 8 MEd 1e (Special Education) c
2a Boston University, 1973.
21 a Ed.D. 1c (Neuropsychology) c
2a Boston University, 1977.
21 9 M.D. 15 (Medicine) c
2a McGill University, 1985.
c
3
3
3
3
90
Permanent link21 9 B.A. 1b (Psych/Soc/Engl) c
26 Union College, 1972.
21 8 MEd 1e (Special Education) c
2a Boston University, 1973.
21 a Ed.D. 1c (Neuropsychology) c
2a Boston University, 1977.
21 9 M.D. 15 (Medicine) c
2a McGill University, 1985.
c
2 29
21
1e
1d
24
5e
8
9e KEY WORDS: frontotemporal degeneration, neurolinguistics, social disorders, executive functioning, neuroimaging, cerebrospinal fluid, plasma, genetics
8
22e DESCRIPTION OF RESEARCH: We assess behavioral, imaging and biofluid measures in patients with frontotemporal degeneration spectrum disorders, including primary progressive aphasia, behavioral variant FTD, amyotrophic lateral sclerosis, corticobasal degeneration and progressive supranuclear palsy. We also study parkinson spectrum disorders. The goal is to identify the best set of behavioral, neuroimaging and biofluid measures that reflect the underlying proteinopathy in each of these patient groups. We participate in clinical treatment trials.
e 7 1d 1f
27
Description of Research Expertise
56 RESEARCH INTERESTS: Biomarker studies in neurodegenerative diseases.8
9e KEY WORDS: frontotemporal degeneration, neurolinguistics, social disorders, executive functioning, neuroimaging, cerebrospinal fluid, plasma, genetics
8
22e DESCRIPTION OF RESEARCH: We assess behavioral, imaging and biofluid measures in patients with frontotemporal degeneration spectrum disorders, including primary progressive aphasia, behavioral variant FTD, amyotrophic lateral sclerosis, corticobasal degeneration and progressive supranuclear palsy. We also study parkinson spectrum disorders. The goal is to identify the best set of behavioral, neuroimaging and biofluid measures that reflect the underlying proteinopathy in each of these patient groups. We participate in clinical treatment trials.
e 7 1d 1f